Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $90.6667.

A number of research analysts have recently issued reports on the company. Guggenheim raised their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Monday, May 4th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th.

Insider Buying and Selling

In other news, General Counsel Bryan Wahl sold 4,231 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the sale, the general counsel directly owned 63,959 shares in the company, valued at approximately $4,285,253. This represents a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 4,174 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $279,658.00. Following the sale, the insider owned 35,028 shares of the company’s stock, valued at approximately $2,346,876. This represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,391 shares of company stock valued at $5,432,035 over the last three months. 9.64% of the stock is owned by corporate insiders.

Institutional Trading of Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its holdings in Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after buying an additional 291 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Tarsus Pharmaceuticals by 367.1% in the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after buying an additional 558 shares during the period. Comerica Bank lifted its holdings in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after buying an additional 705 shares during the period. Truvestments Capital LLC lifted its holdings in Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its holdings in Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares during the period. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Stock Up 0.3%

TARS opened at $59.83 on Friday. The stock has a market cap of $2.57 billion, a PE ratio of -52.48 and a beta of 0.52. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $85.25. The business’s fifty day simple moving average is $67.85 and its 200 day simple moving average is $71.66.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million for the quarter, compared to analysts’ expectations of $149.60 million. As a group, research analysts expect that Tarsus Pharmaceuticals will post -0.7 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.